Trial Profile
Evaluation of Effectiveness and Safety of XIENCE PRIME in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ISIS-PRIME
- 19 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Jul 2014 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 28 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.